The statistical methods scientists use to analyze outcomes from clinical trials in amyotrophic lateral sclerosis (ALS) vary widely, and these differences may make some trials prone to generating ...
An expert interview explores the scientific necessity of patient experience data in amyotrophic lateral sclerosis drug ...
A NEW PUBLICATION IN THE MEDICAL JOURNAL MUSCLE & NERVE VALIDATES THE USE OF THE RATE OF DECLINE OF ALSFRS-R SCORE (ΔFS) FOR THE DESIGN OF CLINICAL STUDIES AND THE TREATMENT CHOICE FOR AMYOTROPHIC ...
CNM-Au8 treated participants in the HEALEY ALS Platform Trial with substantial neurofilament light (NfL) declines (CNM-Au8 NfL Responders) demonstrated significant clinical improvements in survival, ...
Findings showed treatment with Relyvrio was not associated with a statistically significant difference from baseline in ALSFRS-R total score at week 48 compared with placebo. Topline results were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results